BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21283084)

  • 1. The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML.
    Haferlach C; Bacher U; Haferlach T; Dicker F; Alpermann T; Kern W; Schnittger S
    Leukemia; 2011 May; 25(5):874-7. PubMed ID: 21283084
    [No Abstract]   [Full Text] [Related]  

  • 2. Myelodysplastic syndrome with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) has a high risk for progression to acute myeloid leukemia.
    Cui W; Sun J; Cotta CV; Medeiros LJ; Lin P
    Am J Clin Pathol; 2011 Aug; 136(2):282-8. PubMed ID: 21757602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
    Haferlach C; Bacher U; Grossmann V; Schindela S; Zenger M; Kohlmann A; Kern W; Haferlach T; Schnittger S
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1079-85. PubMed ID: 22887804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a dual-color, double fusion FISH assay to detect RPN1/EVI1 gene fusion associated with inv(3), t(3;3), and ins(3;3) in patients with myelodysplasia and acute myeloid leukemia.
    Shearer BM; Sukov WR; Flynn HC; Knudson RA; Ketterling RP
    Am J Hematol; 2010 Aug; 85(8):569-74. PubMed ID: 20556821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The New Clinicopathologic and Molecular Findings in Myeloid Neoplasms With inv(3)(q21q26)/t(3;3)(q21;q26.2).
    Wang HY; Rashidi HH
    Arch Pathol Lab Med; 2016 Dec; 140(12):1404-1410. PubMed ID: 27628325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.
    Rogers HJ; Vardiman JW; Anastasi J; Raca G; Savage NM; Cherry AM; Arber D; Moore E; Morrissette JJ; Bagg A; Liu YC; Mathew S; Orazi A; Lin P; Wang SA; Bueso-Ramos CE; Foucar K; Hasserjian RP; Tiu RV; Karafa M; Hsi ED
    Haematologica; 2014 May; 99(5):821-9. PubMed ID: 24463215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Myelodysplastic syndromes and acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) abnormality].
    Calderón-Cabrera C; Falantes JF; Bernal R; Pérez-Simón JA
    Med Clin (Barc); 2015 Sep; 145(5):224-6. PubMed ID: 25190583
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
    Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
    J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelodysplastic syndrome/acute myeloid leukemia with t(3;21)(q26.2;q22) is commonly a therapy-related disease associated with poor outcome.
    Li S; Yin CC; Medeiros LJ; Bueso-Ramos C; Lu G; Lin P
    Am J Clin Pathol; 2012 Jul; 138(1):146-52. PubMed ID: 22706870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of atypical myelodysplastic syndrome with micromegakaryocytes, normal platelet count, and t(3;12)(q21;p13) with inv(3)(q21q26).
    Schnittger S; Schoch C; Streubel B; Hinrichs HF; Otremba B; Parwaresch R; Fonatsch C
    Genes Chromosomes Cancer; 1997 Nov; 20(3):292-8. PubMed ID: 9365837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unusual findings of acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): A multicenter study.
    Gong X; Yu T; Tang Q; Fu Y; Wu J; Zhu Y; Tu H; Ge H; Lu X; Gong D; Zhao X
    Int J Lab Hematol; 2019 Jun; 41(3):380-386. PubMed ID: 30793839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
    Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
    Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26).
    Fonatsch C; Gudat H; Lengfelder E; Wandt H; Silling-Engelhardt G; Ludwig WD; Thiel E; Freund M; Bodenstein H; Schwieder G
    Leukemia; 1994 Aug; 8(8):1318-26. PubMed ID: 8057667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Characteristics of cases with chromosome 3q21q26 aberrations].
    Zhang Y; He Q; Shi Y; Dang H; Qiu JY; Huang XJ; Lu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):22-5. PubMed ID: 18315893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript.
    Park TS; Choi JR; Yoon SH; Song J; Kim J; Kim SJ; Kwon O; Min YH
    Cancer Genet Cytogenet; 2008 Dec; 187(2):61-73. PubMed ID: 19027486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
    Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
    Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells.
    Larsson N; Billström R; Lilljebjörn H; Lassen C; Richter J; Ekblom M; Fioretos T
    Cancer Genet Cytogenet; 2010 Jun; 199(2):89-95. PubMed ID: 20471511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features.
    Wang SA; Jabbar K; Lu G; Chen SS; Galili N; Vega F; Jones D; Raza A; Kantarjian H; Garcia-Manero G; McDonnell TJ; Medeiros LJ
    Leukemia; 2010 Apr; 24(4):740-7. PubMed ID: 20072149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biology and clinical features of myeloid neoplasms with inv(3)(q21q26) or t(3;3)(q21q26).
    Sperr W; Valent P
    Leuk Lymphoma; 2007 Nov; 48(11):2096-7. PubMed ID: 17990175
    [No Abstract]   [Full Text] [Related]  

  • 20. The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Lu D; Nounou R; Beran M; Estey E; Manshouri T; Kantarjian H; Keating MJ; Albitar M
    Cancer; 2003 Jan; 97(2):441-9. PubMed ID: 12518368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.